Replies to post #3596 on Idenix Pharmaceuticals (IDIX)

[bladerunner1717]

Dew,

You've been strangely silent on J.P's departure. Are you having misgivings about IDIX's ability to compete in the HCV arena? Why do you explain J.P.'s rather sudden departure?

Was J.P. the "brains" of the outfit or are other science types more responsible for the drug development pipeline?


Bladerunner

[DewDiligence]

IDIX Insider Shareholdings

[Updated for resignation of JP Sommadossi and award of
300K options to Ron Renaud, the former CFO who is now CEO.
Options listed below include vested and non-vested holdings.]

 
                             Shares     Options  
 Officers 
 Ron Renaud† (CEO)            15,000     855,000 
 Doug Mayers (CMO)            30,000     300,000 
 David Standring (EVP/Bio)    67,575     150,000 
 Maria Stahl‡ (Gen Counsel)        0     150,000 
 Paul Fanning (SVP/HR)         1,333     235,000 
  
 Directors 
 Charles Cramb                 7,200     160,000 
 Wayne Hockmeyer              41,708     120,000 
 Thomas Hodgson               92,324     120,000 
 Tamar Howson                      0      38,333 
 Denise Pollard-Knight             0     100,000 
 Robert Pelzer*                    0           0 
 Anthony Rosenberg*                0           0 
 ========================  =========   ========= 
 All 12 insiders             255,140   2,528,333

*Directors appointed by NVS; they do not directly own IDIX
shares or options, but NVS itself is a major shareholder.

†Named CEO and director 10/28/10.

‡Hired 10/13/10.